Medical Devices

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A Filipino student's award-winning bathroom design highlights a major market shift. LIXIL's American Standard is capitalizing on the multigenerational home trend.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

A half-million dollar grant is just the start. A new public-private alliance is mobilizing to fight blast-induced brain injuries. Here's the story behind the numbers.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

An AMWC 2026 award for RRS® HA Long Lasting signals a market shift. How Skin Tech Pharma Group is creating a new category beyond fillers and boosters.

Internet titan MrBeast is leveraging his billion-follower empire to tackle a critical blood shortage, aiming to save 1,000 lives in a single day.

CONMED appoints John Gallagher, a seasoned MedTech CFO, to navigate market headwinds and drive a new chapter of financial performance and shareholder value.

An Arkansas lab's $30 million settlement with the DOJ offers a rare look into 'lean lab' models and the fine line between business and patient care.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

Kilroy Realty’s major debt restructuring isn't just a financial footnote; it's a strategic masterclass in navigating market turmoil and unlocking future growth.

Delisted and facing market headwinds, Allurion is executing a reverse stock split. Can this financial maneuver revive its stock and fund its U.S. expansion?

With a $110M boost, Nyxoah is bringing its innovative, battery-free sleep apnea device to the US. Is this the disruption patients have been waiting for?